OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Cristofanilli on Applications for Liquid Biopsy–Based MRD Testing in Breast Cancer

October 25th 2024

Massimo Cristofanilli, MD, discusses the use of circulating tumor DNA for minimal residual disease detection in patients with breast cancer.

Dr Saad on the Safety Profile of Darolutamide Plus ADT in mHSPC

October 25th 2024

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the safety findings from the phase 3 ARANOTE trial investigating darolutamide plus ADT in patients with mHSPC.

Dr Nooka on Integrating Bispecific Antibodies Into the Community Treatment Paradigm for Multiple Myeloma

October 25th 2024

Ajay K. Nooka, MD, MPH, FACP, discusses the integration of bispecific antibodies into the community treatment paradigm for multiple myeloma.

Dr Inra on the Role of the Surgeon in Early-Stage Lung Cancer

October 25th 2024

Matthew Lawrence Inra, MD, discusses the role of the thoracic surgeon in treatment decision-making for patients with early-stage lung cancer.

Dr Miller on the Efficacy of Selinexor in TP53 Wild-Type Endometrial Cancer

October 25th 2024

David S. Miller, MD, discusses the efficacy of selinexor in patients with advanced or recurrent TP53 wild-type endometrial cancer.

Dr Mok on the Efficacy of Taletrectinib in ROS1+ NSCLC

October 25th 2024

Tony S. K. Mok, BMSc, MD, FASCO, discusses efficacy findings from a pooled analysis of the TRUST-I and TRUST-II trials of taletrectinib in ROS1+ NSCLC.

Dr Bekaii-Saab on Frontline Treatment Considerations for BRCA1/2+ Pancreatic Cancer

October 25th 2024

Tanios Bekaii-Saab, MD, FACP, discusses the evolving treatment paradigm for BRCA1- and BRCA2-positive pancreatic cancer in the first-line setting.

Dr Awan on the Evolving Role of Bispecific Antibodies Treatment in DLBCL

October 25th 2024

Farrukh Awan, MD, discuses the evolving role of bispecific antibodies in the treatment paradigm of diffuse large B-cell lymphoma.

Dr Battiwalla on Limitations to CAR T-Cell Therapy Access in Hematologic Malignancies

October 24th 2024

Minoo Battiwalla, MD, MS, discusses both the benefits and the limitations of treatment with CAR T-cell therapy across hematologic malignancies.

Dr Ma on Interim Efficacy and Safety Data With RLY-2608 in PI3Kα-Mutant HR+/HER2– Breast Cancer

October 24th 2024

Cynthia X. Ma, MD, PhD, discusses positive interim data from the phase 1 ReDiscover trial in PI3Kα-mutated HR-positive, HER2-negative breast cancer.

Dr Patel on Findings From the TRUST-II Trial in ROS1+ NSCLC

October 24th 2024

Jyoti Patel, MD, discusses the implications of the TRUST-II trial in locally advanced or metastatic ROS1-positive NSCLC, regardless of prior TKI exposure.

Dr Gordon on the Clinical Implications of the TRANSCEND NHL 001 Trial of Liso-Cel in R/R MCL

October 24th 2024

Leo I. Gordon, MD, discusses the clinical implications of findings from the mantle cell lymphoma cohort of the TRANSCEND NHL 001 trial evaluating liso-cel.

Dr Yuh on the Role of Genetic Factors in Risk Stratification for Prostate Cancer

October 24th 2024

Bertram Yuh, MD, MISM, MSHCPM, discusses the role of genetic factors, such as BRCA mutations, in the risk stratification of patients with prostate cancer.

Dr Drilon on Efficacy Results With Taletrectinib in ROS1+ NSCLC

October 23rd 2024

Alexander Drilon, MD, discusses efficacy findings from the TRUST-I and TRUST-II trials in patients with ROS1+ non–small cell lung cancer.

Dr Rimm on Limitations With IHC Testing in HER2-Low and HER2-Ultralow Breast Cancer

October 23rd 2024

David Rimm, MD, discusses the current limitations of immunohistochemistry diagnostic kits for HER2-low and HER2-ultralow breast cancer.

Dr Foster on Daratumumab/Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma

October 23rd 2024

Laahn Ho Foster, MD, discusses the potential role of daratumumab plus lenalidomide maintenance in multiple myeloma after ASCT.

Dr Fisher on Mechanisms of Resistance with Covalent BTK Inhibitors in CLL

October 23rd 2024

David C. Fisher, MD, discusses resistance mechanisms observed among patients with CLL who were previously treated with covalent BTK inhibitors.

Dr Ducreux on the Potential Use of Liver Transplantation Plus Chemo for CRC Liver Metastases

October 23rd 2024

Michel Ducreux, MD, PhD, discusses the rationale for the TRANSMET trial in patients with CRC liver metastases, highlighting the significance of data from the trial.

Dr Dimopoulos on Patient Reported Outcomes With BPd in Pretreated R/R Multiple Myeloma

October 23rd 2024

Meletios A. Dimopoulos, MD, discusses patient-reported outcomes with BPd in pretreated patients with relapsed/refractory multiple myeloma.

Dr Friedlander on the Design and Methods of the Duravelo-2 Trial in Urothelial Cancer

October 23rd 2024

Terence W. Friedlander, MD, discusses the design and methodology of the Duravelo-2 study of zelenectide pevedotin in advanced/metastatic urothelial cancer.